Havemeyer Place’s Quest Diagnostics DGX Stock Holding History

Havemeyer Place’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,663	Closed	-$1.7M	–	556
2026 Q1	$1.7M	Buy	8,663 +8,261	+2,055%	+$1.61M	0.2%	190
2025 Q4	$69.8K	Buy	+402	New	+$73.2K	0.01%	483

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Havemeyer Place's DGX Position: Q2 2026 in Review

Havemeyer Place sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 8,663 shares — an estimated $1.7M sold.

Havemeyer Place first reported a position in DGX in Q4 2025 and held it in 2 quarters. The position peaked at $1.7M in Q1 2026. 1,105 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Havemeyer Place reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
Havemeyer Place sold 8,663 Quest Diagnostics shares in Q2 2026, an estimated $1.7M.
Havemeyer Place first reported a position in Quest Diagnostics in Q4 2025 and held it in 2 quarters.
Havemeyer Place's Quest Diagnostics position peaked at $1.7M in Q1 2026.
1,105 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Havemeyer Place's 13F filing for Q2 2026, filed 13 Aug 2026.